NCT07009145View on ClinicalTrials.gov

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Interventions
DRUG

QL1706

QL1706 (Iparomlimab and Tuvonralimab) is administered at a dose of 5 mg/kg via intravenous infusion on Day 1 of each 3-week cycle (Q3W).

DRUG

Bevacizumab

Bevacizumab is administered at a dose of 7.5 mg/kg every 3 weeks (Q3W) via intravenous (iv) infusion.

Trial Locations (1)

250000

The First Affiliated Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
collaborator

Linyi Tumour Hospital

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

Qingdao Central Hospital

OTHER

lead

Qianfoshan Hospital

OTHER